Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA accredits GS1, HIBCC for issuing device identifiers as UDI rule architect departs

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration has accredited two global standards organizations, GS1 and the Health Industry Business Communications Council (HIBCC), for issuing unique device identifiers to support the implementation of the agency's new UDI regulations1,2. Separately, Jay Crowley, who was instrumental in authoring the FDA's UDI rule, is leaving the agency to join private consultancy firm USDM Life Sciences3.

You may also be interested in...



New Draft Guidance From FDA Paints Way Forward For Unique Device Identifiers

US FDA lays out for manufacturers how they should cobble together Unique Device Identifiers in a 10-page July 25 draft guidance. The document is intended to be a handy manual for firms as they work to meet UDI requirements and deadlines set by the agency.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

EU Regulators Explain How To Ensure Transitioned Trials Align With CTR

Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT040179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel